List of Excipients in Branded Drug EXBLIFEP

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Allecra Therapeutics SAS	EXBLIFEP	cefepime hydrochloride, enmetazobactam	83289-101	ARGININE	2034-02-22

EXBLIFEP Excipient Strategy and Commercial Opportunities

Last updated: October 19, 2026

EXBLIFEP, the fixed-dose intravenous combination of cefepime and enmetazobactam, is positioned as a hospital antibiotic for adults with complicated urinary tract infections, including acute pyelonephritis, caused by susceptible Gram-negative bacteria. Its excipient strategy is commercially important because the product must stabilize two active ingredients in a high-dose sterile powder while supporting rapid pharmacy preparation and predictable intravenous administration.

The principal formulation opportunity is not a differentiated oral or outpatient dosage form. It is a hospital-use platform built around stability, reconstitution speed, compatibility, supply reliability, and controlled antimicrobial stewardship.

What is EXBLIFEP and how is it formulated?

EXBLIFEP contains cefepime, a fourth-generation cephalosporin, and enmetazobactam, a beta-lactamase inhibitor. The FDA-approved dosage is 2.5 g intravenously every eight hours, infused over two hours in adults with complicated urinary tract infections and pyelonephritis [1].

Attribute	EXBLIFEP
Active ingredients	Cefepime and enmetazobactam
Approved strength	2 g cefepime plus 0.5 g enmetazobactam per vial
Dosage form	Sterile powder for intravenous solution
Administration	Intravenous infusion over two hours
Approved indication	Complicated urinary tract infections, including pyelonephritis
FDA approval	February 22, 2024
Applicant	Allecra Therapeutics
FDA pathway	New drug application
Primary commercial setting	Hospital and acute-care infectious disease treatment

The product is supplied as a single-dose vial. The formulation uses L-arginine as an inactive ingredient and pH-control component. The use of arginine is consistent with the formulation requirements of cefepime, which is commonly supplied with arginine to support solution stability and pH management [1].

The formulation does not depend on a complex delivery device, lipid carrier, polymer system, or preservative system. Its technical value lies in maintaining chemical stability in a dry sterile cake and producing a clear intravenous solution after reconstitution.

Which excipients are used in EXBLIFEP?

The principal disclosed excipient is L-arginine. The drug product is a sterile powder that is reconstituted before intravenous infusion. The label does not identify a broad excipient platform comparable to the excipient systems used in long-acting injectables, liposomal products, or biologics [1].

L-arginine

L-arginine has several potential functions in the product:

• pH adjustment and buffering support
• Improved cefepime stability in the solid and reconstituted states
• Support for drug-solubility control
• Compatibility with parenteral administration
• Use in a conventional hospital compounding workflow

The excipient also creates a regulatory and manufacturing constraint. The amount of arginine must be controlled because the product is administered repeatedly in seriously ill patients, often with renal impairment. Although the arginine quantity in a single dose is not generally positioned as a primary safety concern, excipient load becomes more relevant in patients receiving prolonged courses or multiple arginine-containing medicines.

Sterile powder architecture

A sterile powder presentation provides several commercial advantages:

1. It improves shelf-life compared with a ready-to-use aqueous solution.
2. It limits degradation of cefepime and enmetazobactam during storage.
3. It reduces the need for refrigerated liquid distribution if the approved storage conditions permit room-temperature handling.
4. It allows hospitals to reconstitute the drug near the time of administration.

The tradeoff is operational. Pharmacy staff must reconstitute the vial, select a compatible diluent, prepare the final infusion, and observe the product's in-use stability limits.

How does the EXBLIFEP excipient strategy compare with competing antibiotics?

EXBLIFEP competes with established beta-lactam/beta-lactamase inhibitor products, including ceftazidime-avibactam, meropenem-vaborbactam, imipenem-cilastatin-relebactam, and cefiderocol. These products also rely on sterile powder presentations because high-dose beta-lactam combinations are difficult to maintain as stable aqueous products.

Product	Active combination	Typical dosage form	Primary formulation issue	Commercial implication
EXBLIFEP	Cefepime/enmetazobactam	Sterile powder vial	Dual-drug stability and arginine-containing formulation	Familiar cefepime backbone with beta-lactamase inhibition
AVYCAZ	Ceftazidime/avibactam	Sterile powder vial	Reconstitution and infusion preparation	Established hospital formulary presence
VABOMERE	Meropenem/vaborbactam	Sterile powder vial	High-dose carbapenem preparation	Strong activity against selected resistant Enterobacterales
RECARBRIO	Imipenem/cilastatin/relebactam	Sterile powder vial	Three-component compatibility and stability	Carbapenem-based positioning
FETROJA	Cefiderocol	Sterile powder vial	High-dose infusion and preparation burden	Siderophore-cephalosporin differentiation

EXBLIFEP's excipient profile is commercially competitive because it uses a conventional hospital dosage form. It does not require specialized administration equipment. Its principal differentiation must come from microbiology, clinical outcomes, resistance coverage, dosing convenience, and formulary economics rather than from excipient novelty.

What formulation patents protect EXBLIFEP?

The commercial protection for EXBLIFEP is likely to be distributed across several patent categories:

• Enmetazobactam composition-of-matter patents
• Cefepime/enmetazobactam combination patents
• Formulation and stability patents
• Methods of treating resistant Gram-negative infections
• Processes for preparing enmetazobactam
• Crystalline forms, salts, or intermediates
• Manufacturing controls for sterile drug product

The strongest protection generally comes from composition-of-matter and combination patents. Excipient-specific claims can supplement that protection but are less valuable if competitors can achieve a commercially acceptable product with a different buffer or stabilizer.

A formulation patent directed narrowly to arginine concentration, pH, powder properties, or reconstitution stability may create a development barrier, but it is usually easier to design around than a patent covering the active combination itself. A broad claim covering a stable cefepime/enmetazobactam injectable composition would have greater commercial significance than a claim limited to one excipient ratio.

Public FDA prescribing information confirms the approved product composition and dosage form but does not by itself establish the complete patent estate, patent expiration dates, or Orange Book listing status [1]. Patent and Orange Book conclusions require review of current FDA listing data and the relevant national patent registers.

When does EXBLIFEP lose regulatory exclusivity?

EXBLIFEP received FDA approval in February 2024. The product received Qualified Infectious Disease Product treatment, which can provide five additional years of exclusivity under the Generating Antibiotic Incentives Now framework if the statutory requirements are met [2].

The relevant exclusivity concepts are distinct:

Protection type	Relevance to EXBLIFEP
QIDP exclusivity	Potential five-year extension to applicable exclusivity
New chemical entity exclusivity	Depends on FDA's treatment of the active ingredient and application
Patent exclusivity	Depends on issued patents, expiration dates, terminal disclaimers, and adjustments
Pediatric exclusivity	Could add six months if awarded after qualifying pediatric studies
Orphan exclusivity	Not the principal pathway for the approved indication

The earliest generic entry date cannot be determined from the FDA approval date alone. It depends on the applicable patents, listed patent use codes, patent-term adjustment, pediatric extensions, regulatory exclusivity, and any Paragraph IV litigation or settlement.

What is the Orange Book status of EXBLIFEP?

The Orange Book is the central FDA source for approved drug products, therapeutic equivalence evaluations, and listed patents for eligible small-molecule products. EXBLIFEP is a small-molecule injectable combination and may have patent information listed under its approved NDA, subject to FDA listing decisions and sponsor submissions.

An Orange Book review should focus on:

• NDA 217630
• Listed patents covering cefepime/enmetazobactam
• Patent expiration dates
• Pediatric exclusivity
• Use codes for complicated urinary tract infections and pyelonephritis
• Whether listed patents cover the drug product, active ingredient, or method of use

A generic applicant could seek approval through an abbreviated new drug application if it can establish pharmaceutical equivalence, bioequivalence where applicable, and compliance with injectable-product requirements. For a sterile powder combination, the principal development issues include active-ingredient identity, strength, formulation composition, reconstitution performance, sterility, particulate control, and container-closure integrity.

Which companies are likely to challenge EXBLIFEP?

Potential challengers include generic injectable manufacturers with established sterile beta-lactam production capabilities. The most credible candidates are companies that already manufacture hospital anti-infective products, including large generic suppliers and contract manufacturers.

A Paragraph IV challenge would be more likely when:

• A high-value hospital market has developed.
• The active combination has sufficient purchasing volume.
• Patent claims appear narrow or vulnerable.
• The challenger can reproduce the formulation without infringing formulation claims.
• The product has a clear FDA regulatory pathway.
• The expected launch price supports sterile manufacturing investment.

The commercial case is weaker if hospital uptake remains limited, infectious disease specialists restrict use, or the product is reserved for resistant organisms. A generic applicant may also avoid challenging a strong composition patent and instead target later-expiring formulation or method-of-use patents.

No material EXBLIFEP Paragraph IV litigation or settlement terms are established in the sources cited here. The absence of a reported challenge does not establish that no confidential patent certifications or pre-litigation activity exist.

What generic entry risks exist for EXBLIFEP?

Generic entry risk is moderate in technical terms but depends heavily on market size and patent scope.

Technical barriers

The main manufacturing barriers are:

• Sterile manufacture of a dual-active powder
• Consistent cefepime-to-enmetazobactam ratio
• Control of degradation products
• Reconstitution clarity and particulate limits
• Container-closure integrity
• Stability under shipping and hospital storage conditions
• Validation of the final infusion concentration
• Reliable supply of pharmaceutical-grade enmetazobactam

Enmetazobactam is a newer active ingredient than cefepime. Its manufacturing process, intermediate supply chain, and impurity profile may create more difficulty than the cefepime component.

Legal barriers

The most important legal questions are whether issued patents cover:

1. Enmetazobactam itself.
2. The cefepime/enmetazobactam combination.
3. The approved treatment method.
4. The commercial formulation.
5. A specific pH or excipient system.
6. Manufacturing processes that are difficult to design around.

A formulation-only estate generally provides weaker long-term protection than a valid composition-of-matter patent. A method-of-use patent may still delay practical substitution if the approved indication and use code are broad enough to cover the principal hospital market.

What commercial opportunities exist for EXBLIFEP excipients?

The largest excipient opportunities are incremental rather than transformational.

Ready-to-use presentations

A ready-to-use or premixed infusion could reduce pharmacy labor and preparation errors. The development burden would include aqueous stability, container compatibility, refrigerated or frozen distribution, extractables and leachables, and shipping validation. A premixed bag could also reduce waste in hospitals with high antibiotic utilization.

Extended stability after reconstitution

Longer in-use stability could support centralized pharmacy preparation and reduce discarded doses. This opportunity is particularly relevant to health systems that prepare antibiotics in batches or operate overnight with limited pharmacy staffing.

Smaller-dose and renal-adjustment presentations

Renal dose adjustment is important because cefepime exposure is strongly affected by kidney function. Vial sizes designed for common renal-adjusted regimens could reduce wastage and improve dose preparation. This strategy may require new strengths and potentially separate FDA submissions.

Premixed pharmacy products

A pharmacy bulk package or institutional-use presentation could target large hospitals and infusion centers. The value would come from labor reduction, standardized preparation, and lower compounding burden rather than improved antimicrobial activity.

Alternative buffering systems

A formulation using a different stabilizer or buffer could create a design-around pathway if arginine-related patents are enforceable. The alternative must preserve cefepime and enmetazobactam stability without creating new toxicity, compatibility, or administration problems.

What is the FDA regulatory status of EXBLIFEP?

The FDA approved EXBLIFEP on February 22, 2024, for adults with complicated urinary tract infections, including acute pyelonephritis, caused by susceptible microorganisms [1]. The approval was based on clinical and microbiological data supporting the cefepime/enmetazobactam combination in the target infection setting.

The approved indication is narrower than a broad hospital label for all resistant Gram-negative infections. That limitation affects commercial adoption, formulary placement, and method-of-use patent value. Expansion into hospital-acquired pneumonia, bloodstream infection, intra-abdominal infection, or empiric treatment would require additional clinical and regulatory support.

How strong is the EXBLIFEP commercial opportunity?

EXBLIFEP addresses a defined need: treatment of serious Gram-negative infections involving beta-lactamase-producing organisms while preserving a cefepime-based treatment option. Its opportunity depends on three factors:

• Demonstrated activity against clinically relevant resistance mechanisms.
• Adoption by hospital stewardship committees.
• Reimbursement and price relative to competing beta-lactamase inhibitor products.

The product is more likely to achieve premium pricing when used as targeted therapy after susceptibility results. Broad empiric use would face stronger stewardship controls and direct competition from established products.

Revenue exposure is concentrated in hospitals rather than retail pharmacies. The addressable market is therefore shaped by formulary contracts, infectious disease protocols, antimicrobial-resistance patterns, and procurement economics. The product's commercial upside is meaningful if it captures resistant Enterobacterales cases, but its sales may be constrained if hospitals reserve it for narrow microbiological scenarios.

How does EXBLIFEP compare with other beta-lactamase inhibitor products?

EXBLIFEP's principal strategic advantage is the cefepime backbone. Cefepime is familiar to hospital prescribers and has established dosing and susceptibility-testing infrastructure. The product must still demonstrate a practical advantage over ceftazidime-avibactam, meropenem-vaborbactam, imipenem-cilastatin-relebactam, and cefiderocol.

The excipient strategy does not materially differentiate EXBLIFEP from these products. Competitive separation will depend on resistance coverage, clinical evidence, dosing burden, infusion duration, formulary cost, and supply reliability.

Key Takeaways

• EXBLIFEP is a sterile powder containing cefepime and enmetazobactam for intravenous infusion.
• L-arginine is the principal disclosed excipient and supports formulation pH and stability.
• The product's formulation is conventional for hospital beta-lactam therapy and does not rely on a novel delivery system.
• The strongest potential patent protection is likely to involve enmetazobactam, the fixed combination, manufacturing processes, and stable injectable compositions.
• FDA approval occurred on February 22, 2024, for complicated urinary tract infections and acute pyelonephritis in adults.
• QIDP treatment may provide five additional years of applicable exclusivity, but the actual generic entry date depends on patents, exclusivity, and litigation.
• The most credible lifecycle opportunities are ready-to-use infusions, longer post-reconstitution stability, smaller vial strengths, and pharmacy-optimized presentations.
• Commercial success will depend more on resistance coverage, stewardship adoption, and hospital procurement than on excipient differentiation.

FAQs

Is L-arginine in EXBLIFEP a therapeutic ingredient?

No. L-arginine is an inactive ingredient used to support the injectable formulation, including pH and stability control. It is not responsible for EXBLIFEP's antibacterial activity.

Can EXBLIFEP be developed as an oral product?

An oral product would require a separate formulation and clinical-development program. Cefepime and enmetazobactam are administered intravenously in the approved product, so an oral version cannot be created through excipient substitution alone.

Could a generic EXBLIFEP use different excipients?

Potentially. A generic manufacturer may use a different inactive-ingredient system if the product meets FDA requirements for pharmaceutical equivalence, quality, stability, safety, and administration. Patent claims directed to a particular formulation could restrict that flexibility.

Does EXBLIFEP have biosimilar competition?

No. EXBLIFEP is a chemically synthesized small-molecule drug combination, not a biologic. Any follow-on product would generally proceed through the generic drug framework rather than the biosimilar pathway.

What is the most valuable EXBLIFEP lifecycle product?

A ready-to-use or pharmacy-premixed infusion is likely the most commercially attractive lifecycle concept because it could reduce reconstitution labor, preparation variability, and dose waste. Its feasibility depends on achieving adequate aqueous stability and maintaining container and shipping compatibility.

References

1. U.S. Food and Drug Administration. (2024). EXBLIFEP (cefepime and enmetazobactam) prescribing information. FDA.

2. U.S. Food and Drug Administration. (2023). Qualified infectious disease product designation and exclusivity provisions under the Food, Drug, and Cosmetic Act. FDA.

3. U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations. FDA.

4. Infectious Diseases Society of America. (2024). IDSA guidance on the treatment of antimicrobial-resistant Gram-negative infections. IDSA.